CASI Pharmaceuticals (CASIF) EBT Margin (2022 - 2025)
CASI Pharmaceuticals (CASIF) reported EBT Margin of 1068.86% for Q4 2025, down 96565.0% on a YoY basis from N/an in Q4 2024, and down 227.33% quarter-over-quarter from 326.54% in Q3 2025.
CASI Pharmaceuticals (CASIF) EBT Margin (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported EBT Margin for 4 years, with the latest figure at 1068.86% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin fell 96565.0% year-over-year to 1068.86%; the trailing twelve-month figure through Dec 2025 stood at 483.5% (down 43519.0% YoY), and the FY2025 full-year result was 221.47%, down 20364.0% from the prior year.
- EBT Margin for Q4 2025 stood at 1068.86%, down from 326.54% in the prior quarter.
- The five-year high for EBT Margin was 234.46% in Q4 2023, with the low at 1068.86% in Q4 2025.
- Historically, EBT Margin has averaged 182.94% across 4 years, with a median of 109.67% in 2024.
- Annual changes were most pronounced in 2023 — EBT Margin jumped 38096 bps — and 2025, when it sank 96565 bps.
- CASI Pharmaceuticals' EBT Margin stood at 146.5% in 2022, then soared by 260 bps to 234.46% in 2023, then plunged by 144 bps to 103.21% in 2024, then tumbled by 936 bps to 1068.86% in 2025.
- The last three EBT Margin figures came in at 1068.86% (Q4 2025), 326.54% (Q3 2025), and 277.03% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | - |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | - |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | - |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | -1,068.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,068.86% |
| Sep 30, 2025 | -326.54% |
| Jun 30, 2025 | -277.03% |
| Mar 31, 2025 | -169.49% |
| Dec 31, 2024 | -103.21% |
| Sep 30, 2024 | -116.13% |
| Jun 30, 2024 | -230.49% |
| Mar 31, 2024 | -282.96% |
| Dec 31, 2023 | 234.46% |
| Sep 30, 2023 | -51.97% |
| Jun 30, 2023 | -95.16% |
| Mar 31, 2023 | -86.41% |
| Dec 31, 2022 | -146.50% |
| Sep 30, 2022 | -54.99% |
| Jun 30, 2022 | -74.75% |
| Mar 31, 2022 | -77.09% |